PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

The PRIME-PPF study is a 24-month observational study following patients with non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung disease — including conditions like connective tissue disease-associated ILD and fibrotic hypersensitivity pneumonitis — to better define and predict which patients will experience progressive pulmonary fibrosis (PPF), a worsening of scarring in the lungs over time. Researchers will collect detailed clinical, imaging, and blood biomarker data at regular intervals to test and validate new ways of classifying disease progression. Eligible participants are adults aged 18–80 with a confirmed diagnosis of non-IPF fibrosing ILD, diagnosed within the past 5 years, who can complete lung function testing and are willing to attend follow-up visits; those on specific antifibrotic drugs like nintedanib or currently enrolled in interventional trials are excluded. Participation involves regular clinic visits, lung function tests, CT scans, and blood draws over 24 months. This summary was prepared using AI to help patients understand the study in plain language.